Precision BioLogic Leads the Way in Hemophilia Testing

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Precision-BioLogic

More Like This

PR Newswire associated0

Precision BioLogic Acquires George King Bio-Medical

PR Newswire associated0

Novo Nordisk submits Biologics License Application (BLA) to FDA for Mim8; an investigational, prophylaxis treatment for people living with hemophilia A with or without inhibitors

PR Newswire associated0

Octapharma AG: Indirect comparison data indicate that personalised prophylaxis with Nuwiq® may lead to fewer patients with haemophilia A having bleeds than with other recombinant factor VIII products

Roche launches three new Factor Xa inhibitor coagulation tests to meet growing patient need

PR Newswire associated0

Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM

PR Newswire associated0

Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026

Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate

PR Newswire associated0

Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig